2012年美国干细胞治疗应用大幅上升
2012-11-29 22:13:00 来源:
Dramatic Rise in Stem Cell Therapy Use in 2012
Stem Cell Company Executives, Scientists, Investors and Physicians will present data Feb. 19,2013 at the 8th Annual New York Stem Cell Summit in New York City
PR Newswire ([url]http://s.tt/1uSNJ[/url])
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."
Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.
Aastrom Biosciences, Inc.
Advanced Cell Technology
Aldagen, Inc.
AllCells, LLC.
Aruna Biomedical, Inc.
Athersys, Inc.
Bioheart Inc.
BioLife Solutions
BioTime Inc./Embryome Sciences, Inc.
Brainstorm Cell Therapeutics
Case Western Reserve University
CellCyte Genetics Corp.
Celgene Corporation
Celtigen Therapeutics
Cord Blood America, Inc. (CBAI.OB)
Core Dynamics Ltd.
Cytori Therapeutics, Inc.
Gamida Cell Ltd.
Garnet BioTherapeutics, Inc.
Histogen Inc
INCELL Corporation LLC
International Stem Cell Corporation
Lifenet Health
Lonza Group Ltd.
Medistem Inc.
Mesoblast Limited
MultiCell Technologies [MCET]
Neostem, Inc.
Neuralstem
Opexa Therapeutics, Inc.
Osiris Therapeutics, Inc.
Parcell Labs
Pathfinder Cell Therapy
Pervasis Therapeutics, Inc.
Pluristem Therapeutics, Inc.
Prochon Biotech, Ltd.
Progenitor Cell Therapy, LLC
Stem Cell Innovations
Stem Cell Therapeutics (SCTPF)
StemCells Inc.
TiGenix NV
Tissue Genesis, Inc.
TxCell
Vet-Stem, Inc.
ViaCyte
WuXi AppTec
In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.
Stem Cell Company Executives, Scientists, Investors and Physicians will present data Feb. 19,2013 at the 8th Annual New York Stem Cell Summit in New York City
PR Newswire ([url]http://s.tt/1uSNJ[/url])
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."
Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.
Aastrom Biosciences, Inc.
Advanced Cell Technology
Aldagen, Inc.
AllCells, LLC.
Aruna Biomedical, Inc.
Athersys, Inc.
Bioheart Inc.
BioLife Solutions
BioTime Inc./Embryome Sciences, Inc.
Brainstorm Cell Therapeutics
Case Western Reserve University
CellCyte Genetics Corp.
Celgene Corporation
Celtigen Therapeutics
Cord Blood America, Inc. (CBAI.OB)
Core Dynamics Ltd.
Cytori Therapeutics, Inc.
Gamida Cell Ltd.
Garnet BioTherapeutics, Inc.
Histogen Inc
INCELL Corporation LLC
International Stem Cell Corporation
Lifenet Health
Lonza Group Ltd.
Medistem Inc.
Mesoblast Limited
MultiCell Technologies [MCET]
Neostem, Inc.
Neuralstem
Opexa Therapeutics, Inc.
Osiris Therapeutics, Inc.
Parcell Labs
Pathfinder Cell Therapy
Pervasis Therapeutics, Inc.
Pluristem Therapeutics, Inc.
Prochon Biotech, Ltd.
Progenitor Cell Therapy, LLC
Stem Cell Innovations
Stem Cell Therapeutics (SCTPF)
StemCells Inc.
TiGenix NV
Tissue Genesis, Inc.
TxCell
Vet-Stem, Inc.
ViaCyte
WuXi AppTec
In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.
上一篇:东亚在干细胞创新研究中所面临的独特机遇和挑战
下一篇:日本宣布选定6家机构进行iPS细胞长期保存研究
延伸阅读:
- ·2012年干细胞研究与治疗(2013-06-02)
- ·2012年第一季度细胞治疗产业增长和投资情况(2013-06-02)
- ·美刊评出2012年十大新兴技术 卵子干细胞居首(2012-05-15)
- ·StemCells公司在2012年国际脊髓学会年度科学会议公布中期脊髓损伤的试验数据(2012-09-11)
- ·2012年中美临床与转化医学研讨会论文集(2013-06-06)
分享到:
收藏
频道总排行
频道今日排行
- 3,5762014Q2——生物技术行业走上正轨
- 3,574iPS细胞缓步走向临床
- 3,573全球首例胚胎干细胞疗法试验夭折 成人干细胞研究进展良好
- 3,572哈佛干细胞专家:干细胞技术魅力在于让新药更低价
- 3,572争议干细胞疗法 意大利批准使用
- 3,572诺华敲定与干细胞公司Gamida的交易
- 3,572高丝利用iPS细胞开发化妆品?
- 3,572FDA 美国杜克大学医学院脐带血造血干细胞静脉注射悬浮液...
- 3,572十一位科学家获生命科学巨奖
- 3,571美国先进细胞科技公司开展干细胞治疗眼疾临床试验 效果显著